The pharmaceutical industry is bracing for its most significant "patent cliff" to date, with an estimated $300 billion to $400 billion in revenue from around 200 drugs at risk between 2026 and 2030. This wave of expirations includes high-value assets like Merck's Keytruda, Bristol Myers Squibb and Pfizer's Eliquis, Pfizer's Ibrance, and Eli Lilly's Trulicity. Some estimates suggest that $230 billion in annual sales from blockbuster drugs alone will be lost by 2030, with the top 20 drugs facing expiration accounting for $176.442 billion in sales last year.
Companies like Bristol Myers Squibb and Pfizer face substantial challenges, with BMS staring down a $38 billion growth gap as Eliquis and Opdivo lose exclusivity, comprising over half of its earnings. Merck & Co. and Pfizer also need to close gaps of $23 billion and $21 billion, respectively. Merck's Keytruda, the world's best-selling drug, is expected to peak around $32 billion in 2026 before facing biosimilar competition, representing more than half of the company's sales.
To navigate this crisis, pharmaceutical companies are employing multi-pronged strategies. These include accelerated R&D to develop new blockbusters, lifecycle management through indication expansion, and strategic mergers and acquisitions (M&A). Johnson & Johnson, for instance, has undertaken a $14.6 billion buyout of Intra-Cellular Therapies, while Merck completed a $10 billion purchase of Verona Pharma. Sanofi closed on a deal of up to $9.5 billion for Blueprint Medicines. Companies are also attempting to delay patent expirations and refocus their pipelines on new drug development, with AbbVie serving as a success story by diversifying its revenue stream away from Humira through new drugs like Rinvoq and Skyrizi and M&A deals.
Some companies, like Eli Lilly and Novo Nordisk, are less exposed due to their strong performance in GLP-1 weight loss drugs. However, the industry as a whole is undergoing significant governance and organizational restructuring to protect and reinvent value. The entry of generics and biosimilars typically leads to an over 80% market-share loss for original brands in the first year, emphasizing the urgency for pharmaceutical companies to adapt and innovate to offset these massive revenue losses and maintain growth.
